Elevance Health Inc (ELV) ニュース

Form 8-K - Current report

Elevance Health Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Outlook

4Q 2024 operating revenue of $45.0 billion; FY 2024 of $175.2 billion 4Q 2024 diluted EPS1 of $1.81; adjusted diluted EPS2 of $3.84 FY 2024...

Elevance Health to Hold Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2024 Results on January 23, 2025

Elevance Health (NYSE: ELV) will release fourth quarter and full year 2024 financial results on January 23, 2025, at 6:00 a.m. Eastern Standard...

Form 4 - Statement of changes in beneficial ownership of securities

AM Best Affirms Credit Ratings of Elevance Health, Inc. and Its Subsidiaries

AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “a+”...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Elevance Health Announces Appearance at UBS Global Healthcare Conference

Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at the UBS Global Healthcare Conference in Rancho...

Elevance Health Appoints Nathan Rich Vice President, Investor Relations

Elevance Health (NYSE: ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In...

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities